Pfizer, Merck and Roche have spent years developing drugs that increase production of HDL cholesterol based on the theory that raising the so-called good cholesterol helps ferry artery-clogging plaque from the body.
But new research throws that strategy into question and shows HDL plays no role in preventing heart attacks, said Anne Tybjaerg- Hansen, a study author and clinical biochemistry researcher at Copenhagen University Hospital.
``There is really no evidence that this method is going to work,'' said Tybjaerg-Hansen in a telephone interview. ``This theory has been around for a long time, but this study just doesn't support it.''
More
No comments:
Post a Comment